Sanofi (SNY +1.1%) tetravalent drug, potentially the world's first vaccine against dengue fever,...

|About: Sanofi (SNY)|By:, SA News Editor

Sanofi (SNY +1.1%) tetravalent drug, potentially the world's first vaccine against dengue fever, provided protection against 3 of the virus' 4 strains in a Phase IIb study in Thailand. Dengue fever is spread by mosquitoes and is a threat to almost 3B people; if tetravalent is approved, Sanofi reckons annual sales could top $1B. A Phase III trial is already under way. (PR)